
    
      In the Phase Ia part of the study, tiragolumab is administered as a single agent in
      participants with R/R MM or R/R NHL.

      In the Phase Ib part of the study, tiragolumab is administered in combination with
      daratumumab in participants with R/R MM or with rituximab in participants with R/R NHL for
      whom combination therapy is considered an acceptable treatment option.
    
  